Edesa Biotech Inc 2026年季度报告

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ As of February 12, 2026, the registrant had 8,348,161common shares issued and outstanding. PagePART IFINANCIAL STATEMENTS3Item 1.Financial Statements (Unaudited)3Condensed Interim Consolidated Balance Sheets –December 31, 2025 and September 30, 20253Condensed Interim Consolidated Statements of Operations –Three Months Ended December 31, 2025 and20244Condensed Interim Consolidated Statements of Cash Flows –Three Months Ended December 31, 2025 and20245Condensed Interim Consolidated Statements of Changes in Shareholders' Equity –Three Months EndedDecember 31, 2025 and 20246Notes to Condensed Interim Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures About Market Risk23Item 4.Controls and Procedures23PART IIOTHER INFORMATION24Item 1.Legal Proceedings24Item 1A.Risk Factors24Item 2.Unregistered Sales of Equity Securities and Use of Proceeds24Item 3.Defaults Upon Senior Securities24Item 4.Mine Safety Disclosures24Item 5.Other Information24Item 6.Exhibits252 Edesa Biotech, Inc.Notes to Condensed Interim Consolidated Financial Statements 1.Nature of Operations Edesa Biotech, Inc. (the “Company” or “Edesa”) is a biopharmaceutical company focused on acquiring, developing and commercializingclinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The Company is organized under thelaws of British Columbia, Canada and is headquartered in Markham, Ontario. It operates under its wholly owned subsidiaries, Edesa Biotech The Company’s common shares trade on The Nasdaq Capital Market in the United States under the symbol “EDSA”. Going Concern Thesecondensed interimconsolidated financial statements have been prepared on a going concern basis which presumes the realization ofassets and the discharge of liabilities in the normal course of operations for at least the next twelve months. For the three months ended December 31, 2025, the Company incurred a comprehensive loss of $2.3 million resulting in an accumulateddeficit of $68.2 million. For the three months ended December 31, 2025, the Company had a net cash outflow from operating activities of$2.1 million and ended the quarter with $12.1 million in cash and cash equivalents and a net working capital surplus of $12.0 million. TheCompany’s ability to continue as a going concern is dependent on obtaining additional funding through financings, other strategic activities Thesecondensed interimconsolidated financial statements do not give effect to any adjustments which would be necessary should theCompany be unable to continue as a going concern and, therefore, be required to realize its assets and discharge its liabilities in other than 2.Basis of Presentation The accompanying unaudited condensed interim consolidated financial statements have been prepared in accordance with accountingprinciples generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q.They do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows The accompanying unaudited condensed interim consolidated financial statements include the accounts of the Company and its whollyowned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation. All adjustments (consisting ofnormal recurring adjustments and accruals) considered necessary for a fair presentation of the results of operations for the periods presented Use of estimates The preparation of condensed interim consolidated financial statements in conformity with U.S. GAAP requires management to makeestimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at thedate of the condensed interim financial statements and the reported amounts of revenue and expenses during the period or year. Actualresults could differ from those estimates. Significant areas of judgment and estimation include, but are not limited to, the valuation of Functional and reporting currencies The consolidated condensed interim financial statements of the Company are presented in U.S. dollars, unless otherwise stated,